Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer

References

• Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005; 11:312-9; PMID:15711557; http://dx.doi.org/10.1038/nm1196
   PubMed Web of Science ®Google Scholar
• Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011; 478:197-203; PMID:21976023; http://dx.doi.org/10.1038/nature10491
   PubMed Web of Science ®Google Scholar
• Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, Frederick R, De Plaen E, Uyttenhove C, Wouters J, Masereel B et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci U S A 2012; 109:2497-502; PMID:22308364; http://dx.doi.org/10.1073/pnas.1113873109
   PubMed Web of Science ®Google Scholar
• Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE, Boulden J, Sutanto-Ward E, Soler AP, Laury-Kleintop LD et al. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov 2012; 2:722-35; PMID:22822050; http://dx.doi.org/10.1158/2159-8290.CD-12-0014
   PubMed Web of Science ®Google Scholar
• Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9:1269-74; PMID:14502282; http://dx.doi.org/10.1038/nm934
   PubMed Web of Science ®Google Scholar
• Theate I, van Baren N, Pilotte L, Moulin P, Larrieu P, Renauld JC, Hervé C, Gutierrez-Roelens I, Marbaix E, Sempoux C et al. Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues. Cancer Immunol Res 2015; 3:161-72; PMID:25271151; http://dx.doi.org/10.1158/2326-6066.CIR-14-0137
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Aranda F, Eggermont A, Sautes-Fridman C, Tartour E, Kennedy EP, Platten M, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology 2014; 3:e957994; PMID:25941578; http://dx.doi.org/10.4161/21624011.2014.957994
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol 2016; 37:193-207; PMID:26839260; http://dx.doi.org/10.1016/j.it.2016.01.002
   PubMed Web of Science ®Google Scholar
• Chon SY, Hassanain HH, Gupta SL. Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-gamma-inducible expression of human indoleamine 2,3-dioxygenase gene. J Biol Chem 1996; 271:17247-52; PMID:8663541; http://dx.doi.org/10.1074/jbc.271.29.17247
   PubMed Web of Science ®Google Scholar
• Opitz CA, Wick W, Steinman L, Platten M. Tryptophan degradation in autoimmune diseases. Cell Mol Life Sci 2007; 64:2542-63; PMID:17611712; http://dx.doi.org/10.1007/s00018-007-7140-9
   PubMed Web of Science ®Google Scholar
• Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, Sorenson EC, Popow R, Ariyan C, Rossi F et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011; 17:1094-100; PMID:21873989; http://dx.doi.org/10.1038/nm.2438
   PubMed Web of Science ®Google Scholar
• Litzenburger UM, Opitz CA, Sahm F, Rauschenbach KJ, Trump S, Winter M, Ott M, Ochs K, Lutz C, Liu X et al. Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget 2014; 5:1038-51; PMID:24657910; http://dx.doi.org/10.18632/oncotarget.1637
   PubMed Web of Science ®Google Scholar
• Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27:1160-7; PMID:19204204; http://dx.doi.org/10.1200/JCO.2008.18.1370
   PubMed Web of Science ®Google Scholar
• Stavrum AK, Heiland I, Schuster S, Puntervoll P, Ziegler M. Model of tryptophan metabolism, readily scalable using tissue-specific gene expression data. J Biol Chem 2013; 288:34555-66; PMID:24129579; http://dx.doi.org/10.1074/jbc.M113.474908
   PubMed Web of Science ®Google Scholar
• Roadmap Epigenomics Consortium, Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, Heravi-Moussavi A, Kheradpour P, Zhang Z, Wang J et al. Integrative analysis of 111 reference human epigenomes. Nature 2015; 518:317-30; PMID:25693563; http://dx.doi.org/10.1038/nature14248
   PubMed Web of Science ®Google Scholar
• Rosenbloom KR, Armstrong J, Barber GP, Casper J, Clawson H, Diekhans M, Dreszer TR, Fujita PA, Guruvadoo L, Haeussler M et al. The UCSC Genome Browser database: 2015 update. Nucleic Acids Res 2015; 43:D670-81; PMID:25428374; http://dx.doi.org/10.1093/nar/gku1177
   PubMed Web of Science ®Google Scholar
• Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest 2006; 116:561-70; PMID:16511588; http://dx.doi.org/10.1172/JCI27987
   PubMed Web of Science ®Google Scholar
• Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med 2013; 210:1389-402; PMID:23752227; http://dx.doi.org/10.1084/jem.20130066
   PubMed Web of Science ®Google Scholar
• Pitt JM, Vetizou M, Daillere R, Roberti MP, Yamazaki T, Routy B, Lepage P, Boneca IG, Chamaillard M, Kroemer G et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity 2016; 44:1255-69; PMID:27332730; http://dx.doi.org/10.1016/j.immuni.2016.06.001
   PubMed Web of Science ®Google Scholar
• Rose DP. The influence of sex, age and breast cancer on tryptophan metabolism. Clin Chim Acta 1967; 18:221-5; PMID:5624543; http://dx.doi.org/10.1016/0009-8981(67)90161-1
   PubMed Web of Science ®Google Scholar
• Lyon DE, Walter JM, Starkweather AR, Schubert CM, McCain NL. Tryptophan degradation in women with breast cancer: a pilot study. BMC Res Notes 2011; 4:156; PMID:21615916; http://dx.doi.org/10.1186/1756-0500-4-156
   PubMedGoogle Scholar
• Juhasz C, Nahleh Z, Zitron I, Chugani DC, Janabi MZ, Bandyopadhyay S, Ali-Fehmi R, Mangner TJ, Chakraborty PK, Mittal S et al. Tryptophan metabolism in breast cancers: molecular imaging and immunohistochemistry studies. Nucl Med Biol 2012; 39:926-32; PMID:22444239; http://dx.doi.org/10.1016/j.nucmedbio.2012.01.010
   PubMed Web of Science ®Google Scholar
• Soliman H, Rawal B, Fulp J, Lee JH, Lopez A, Bui MM, Khalil F, Antonia S, Yfantis HG, Lee DH et al. Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry. Cancer Immunol Immunother 2013; 62:829-37; PMID:23344392; http://dx.doi.org/10.1007/s00262-013-1393-y
   PubMed Web of Science ®Google Scholar
• Isla Larrain MT, Rabassa ME, Lacunza E, Barbera A, Creton A, Segal-Eiras A, Croce MV. IDO is highly expressed in breast cancer and breast cancer-derived circulating microvesicles and associated to aggressive types of tumors by in silico analysis. Tumour Biol 2014; 35:6511-9; PMID:24687552; http://dx.doi.org/10.1007/s13277-014-1859-3
   PubMed Web of Science ®Google Scholar
• Jacquemier J, Bertucci F, Finetti P, Esterni B, Charafe-Jauffret E, Thibult ML, Houvenaeghel G, Van den Eynde B, Birnbaum D, Olive D et al. High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma. Int J Cancer 2012; 130:96-104; PMID:21328335; http://dx.doi.org/10.1002/ijc.25979
   PubMed Web of Science ®Google Scholar
• Tang X, Lin CC, Spasojevic I, Iversen ES, Chi JT, Marks JR. A joint analysis of metabolomics and genetics of breast cancer. Breast Cancer Res 2014; 16:415; PMID:25091696; http://dx.doi.org/10.1186/s13058-014-0415-9
   PubMed Web of Science ®Google Scholar
• Yuan H, Kopelovich L, Yin Y, Lu J, Glazer RI. Drug-targeted inhibition of peroxisome proliferator-activated receptor-gamma enhances the chemopreventive effect of anti-estrogen therapy. Oncotarget 2012; 3:345-56; PMID:22538444; http://dx.doi.org/10.18632/oncotarget.457
   PubMed Web of Science ®Google Scholar
• D'Amato NC, Rogers TJ, Gordon MA, Greene LI, Cochrane DR, Spoelstra NS, Nemkov TG, D'Alessandro A, Hansen KC, Richer JK. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer. Cancer Res 2015; 75:4651-64; PMID:26363006; http://dx.doi.org/10.1158/0008-5472.CAN-15-2011
   PubMed Web of Science ®Google Scholar
• Miyan M, Schmidt-Mende J, Kiessling R, Poschke I, de Boniface J. Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer. J Transl Med 2016; 14:227; PMID:27473163; http://dx.doi.org/10.1186/s12967-016-0983-9
   PubMed Web of Science ®Google Scholar
• Stossi F, Madak-Erdogan Z, Katzenellenbogen BS. Estrogen receptor alpha represses transcription of early target genes via p300 and CtBP1. Mol Cell Biol 2009; 29:1749-59; PMID:19188451; http://dx.doi.org/10.1128/MCB.01476-08
   PubMed Web of Science ®Google Scholar
• Dedeurwaerder S, Desmedt C, Calonne E, Singhal SK, Haibe-Kains B, Defrance M, Michiels S, Volkmar M, Deplus R, Luciani J et al. DNA methylation profiling reveals a predominant immune component in breast cancers. EMBO Mol Med 2011; 3:726-41; PMID:21910250; http://dx.doi.org/10.1002/emmm.201100801
   PubMed Web of Science ®Google Scholar
• Fackler MJ, Umbricht CB, Williams D, Argani P, Cruz LA, Merino VF, Teo WW, Zhang Z, Huang P, Visvananthan K et al. Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res 2011; 71:6195-207; PMID:21825015; http://dx.doi.org/10.1158/0008-5472.CAN-11-1630
   PubMed Web of Science ®Google Scholar
• Shi JF, Li XJ, Si XX, Li AD, Ding HJ, Han X, Sun YJ. ERalpha positively regulated DNMT1 expression by binding to the gene promoter region in human breast cancer MCF-7 cells. Biochem Biophys Res Commun 2012; 427:47-53; PMID:22975348; http://dx.doi.org/10.1016/j.bbrc.2012.08.144
   PubMed Web of Science ®Google Scholar
• Xue ZT, Sjogren HO, Salford LG, Widegren B. An epigenetic mechanism for high, synergistic expression of indoleamine 2,3-dioxygenase 1 (IDO1) by combined treatment with zebularine and IFN-gamma: potential therapeutic use in autoimmune diseases. Mol Immunol 2012; 51:101-11; PMID:22424783; http://dx.doi.org/10.1016/j.molimm.2012.01.006
   PubMed Web of Science ®Google Scholar
• Vigneron N, van Baren N, Van den Eynde BJ. Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance. Oncoimmunology 2015; 4:e1003012; PMID:26155395; http://dx.doi.org/10.1080/2162402X.2014.1003012
   PubMed Web of Science ®Google Scholar
• Chung SH, Franceschi S, Lambert PF. Estrogen and ERalpha: culprits in cervical cancer? Trends Endocrinol Metab 2010; 21:504-11; PMID:20456973; http://dx.doi.org/10.1016/j.tem.2010.03.005
   PubMed Web of Science ®Google Scholar
• Srijaipracharoen S, Tangjitgamol S, Tanvanich S, Manusirivithaya S, Khunnarong J, Thavaramara T, Leelahakorn S, Pataradool K. Expression of ER, PR, and Her-2/neu in endometrial cancer: a clinicopathological study. Asian Pac J Cancer Prev 2010; 11:215-20; PMID:20593959
   PubMedGoogle Scholar
• Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2:401-4; PMID:22588877; http://dx.doi.org/10.1158/2159-8290.CD-12-0095
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6:pl1; PMID:23550210; http://dx.doi.org/10.1126/scisignal.2004088
   PubMed Web of Science ®Google Scholar
• Cline MS, Craft B, Swatloski T, Goldman M, Ma S, Haussler D, Zhu J. Exploring TCGA pan-cancer data at the UCSC cancer genomics browser. Sci Rep 2013; 3:2652; PMID:24084870; http://dx.doi.org/10.1038/srep02652
   PubMed Web of Science ®Google Scholar
• Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, Haussler D. The human genome browser at UCSC. Genome Res 2002; 12:996-1006.; PMID:12045153; http://dx.doi.org/10.1101/gr.229102
   PubMed Web of Science ®Google Scholar
• Trump S, Bieg M, Gu Z, Thurmann L, Bauer T, Bauer M, Ishaque N, Röder S, Gu L, Herberth G et al. Prenatal maternal stress and wheeze in children: novel insights into epigenetic regulation. Sci Rep 2016; 6:28616; PMID:27349968; http://dx.doi.org/10.1038/srep28616
   PubMed Web of Science ®Google Scholar